What’s Next for Comprehensive Genomic Profiling in Cancer Care
An expert discusses how comprehensive genomic profiling will continue growing as an essential component of personalized cancer care, expanding into serial testing for resistance monitoring, tumor burden tracking, and potentially earlier-stage cancers as targeted therapies prove effective beyond advanced disease.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
Video content above is prompted by the following:
Incomplete genomic testing can result in patients being left behind without access to potentially beneficial treatment options, emphasizing the critical importance of comprehensive molecular profiling. Biomarker-driven decision-making is essential in metastatic lung cancer due to first-line targeted therapy approvals based on specific genomic drivers. Comprehensive genomic profiling has demonstrated positive patient outcomes including deeper, faster, and more durable responses that improve survival compared with historical controls.
Hatim Husain, MD, and his team have implemented several strategies to align with comprehensive genomic profiling best practices, including creating educational opportunities for staff and ensuring genomic results are easily visible throughout the health care system. They’ve developed accountability cultures where team members understand test result importance and work collaboratively to minimize turnaround times. Electronic medical record optimization includes appropriate genomic data labeling for easy chart identification and patient education about obtaining and understanding their molecular test results.
As cancer care becomes increasingly personalized, comprehensive genomic profiling will continue growing as an essential component of cancer treatment delivery. Future applications include expanded serial testing for resistance monitoring and tumor burden tracking throughout the treatment continuum. The technology may also expand into earlier cancer stages, with ongoing research validating targeted therapies for additional oncogenes in early-stage disease, representing the continued evolution toward precision medicine approaches in oncology care.
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
